Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).
Monsellato I, Alongi F, Bertocchi E, Gori S, Ruffo G, Cassinotti E, Baldari L, Boni L, Pernazza G, Pulighe F, De Nisco C, Perinotti R, Morpurgo E, Contardo T, Mammano E, Elmore U, Delpini R, Rosati R, Perna F, Coratti A, Menegatti B, Gentilli S, Baroffio P, Buccianti P, Balestri R, Ceccarelli C, Torri V, Cavaliere D, Solaini L, Ercolani G, Traverso E, Fusco V, Rossi M, Priora F, Numico G, Franzone P, Orecchia S. Monsellato I, et al. Among authors: fusco v. BMC Cancer. 2019 Dec 16;19(1):1215. doi: 10.1186/s12885-019-6271-3. BMC Cancer. 2019. PMID: 31842784 Free PMC article.
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
Gori S, Clavarezza M, Siena S, Foglietta J, Tarenzi E, Giordano M, Molino A, Graiff C, Fusco V, Alabiso O, Baldini E, Gamucci T, Altavilla G, Dondi D, Venturini M. Gori S, et al. Among authors: fusco v. BMC Cancer. 2012 Apr 30;12:158. doi: 10.1186/1471-2407-12-158. BMC Cancer. 2012. PMID: 22545982 Free PMC article.
RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw.
Fusco V, Campisi G, Numico G, Migliorati CA, Santini D, Bedogni A. Fusco V, et al. J Natl Cancer Inst. 2016 Jul 7;108(9):djw155. doi: 10.1093/jnci/djw155. Print 2016 Sep. J Natl Cancer Inst. 2016. PMID: 27390045 No abstract available.
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR).
Monsellato I, Alongi F, Bertocchi E, Gori S, Ruffo G, Cassinotti E, Baldari L, Boni L, Pernazza G, Pulighe F, De Nisco C, Perinotti R, Morpurgo E, Contardo T, Mammano E, Elmore U, Delpini R, Rosati R, Perna F, Coratti A, Menegatti B, Gentilli S, Baroffio P, Buccianti P, Balestri R, Ceccarelli C, Torri V, Cavaliere D, Solaini L, Ercolani G, Traverso E, Fusco V, Rossi M, Priora F, Numico G, Franzone P, Orecchia S. Monsellato I, et al. Among authors: fusco v. BMC Cancer. 2020 Feb 17;20(1):128. doi: 10.1186/s12885-020-6632-y. BMC Cancer. 2020. PMID: 32066408 Free PMC article.
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088).
Monsellato I, Garibaldi E, Cassinotti E, Baldari L, Boni L, Elmore U, Delpini R, Rosati R, Perinotti R, Alongi F, Bertocchi E, Gori S, Ruffo G, Pernazza G, Pulighe F, De Nisco C, Morpurgo E, Contardo T, Mammano E, Perna F, Menegatti B, Coratti A, Buccianti P, Balestri R, Ceccarelli C, Cavaliere D, Solaini L, Ercolani G, Traverso E, Fusco V, Torri V, Orecchia S. Monsellato I, et al. Among authors: fusco v. Trials. 2020 Jul 25;21(1):678. doi: 10.1186/s13063-020-04568-9. Trials. 2020. PMID: 32711544 Free PMC article.
Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.
Rossi M, Gambino A, Cabras M, Alessio M, Fusco V. Rossi M, et al. Among authors: fusco v. Support Care Cancer. 2021 Aug;29(8):4185-4186. doi: 10.1007/s00520-021-06100-4. Epub 2021 Feb 25. Support Care Cancer. 2021. PMID: 33634351 No abstract available.
Is Medication-Related Osteonecrosis of the Jaws (MRONJ) Associated to Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors? A Word of Cautiousness. Comment on Marcianò et al. Medication-Related Osteonecrosis of the Jaws and CDK4/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health 2020, 17, 9509.
Fusco V, Alessio M, Guglielmini PF, Vincenti M, Fasciolo A, Rossi M. Fusco V, et al. Int J Environ Res Public Health. 2021 Sep 27;18(19):10143. doi: 10.3390/ijerph181910143. Int J Environ Res Public Health. 2021. PMID: 34639444 Free PMC article.
227 results